Bulletin from annual general meeting of SciBase Holding AB (publ) on 16 May 2016

At the annual general meeting of SciBase Holding AB (publ) on 16 May 2016 in
Stockholm the shareholders adopted the below resolutions.
Resolution regarding adoption of the profit and loss account and balance sheet
for the company and the group as well as resolutions in respect of appropriation
of profits and discharge from liability

The meeting resolved to adopt the profit and loss account and balance sheet for
the group and the Company included in the annual report.

The meeting resolved to allocate the profit for the year in accordance with the
board of directors’ proposal, i.e. SEK 242,298,179 was carried forward.

The meeting resolved to discharge the board members and managing director from
liability for their management of the Company's affairs during the preceding
financial year.

Resolution regarding the number of members of the board of directors and
deputies

The meeting resolved that the Company's board of directors shall consist of six
ordinary members and two deputies.

Resolution regarding the remuneration for the board of directors and the auditor

The meeting resolved that fees to the board of directors for the financial year
2016 shall be paid with SEK 150,000 to the chairman of the board and SEK 100,000
to external members of the board of directors who do not own shares, are
founders or represent a larger shareholder in the Company. Board members shall,
provided that the circumstances so allow from a tax perspective and that no
additional costs will be incurred by the Company, be allowed to invoice the fee.

It was resolved that fees to the Company's auditor shall be paid in accordance
with approved current account.

Resolution on guidelines for determination of salary and other remuneration to
senior management

The meeting resolved to adopt guidelines for determination of salary and other
remuneration to senior management in accordance the board’s proposal.

Resolution regarding members of the board of directors and auditor

For the time until the end of the next annual general meeting, the meeting
resolved to elect Andreas Pennervall (new election) Tord Lendau (re-election),
Carsten Browall (re-election), Stig 0llmar (re-election), Per Aniansson (re
-election) and Renee Aguiar-Lucander (re-election) as ordinary members of the
board of directors. Anna Gustafsson (new election) and Victoria Torell (new
election) were elected as deputy members of the board of directors for the time
until the end of the next annual general meeting. Ernst & Young AB was re
-elected as auditor with Björn Ohlsson as responsible auditor for the time until
the end of the next annual general meeting.

Resolution regarding appointment of nominating committee

The meeting resolved to adopt principles for the appointment the nominating
committee for the annual general meeting 2017 in accordance with the nominating
committee’s proposal.

Resolution regarding authorization of the board of directors to issue new
shares, issuance of warrants and/or convertibles

The meeting resolved unanimously to authorize the board of directors to, during
the time until the next annual general meeting, decide upon issuances of new
shares, issuance of warrants and/or convertibles. New issues of shares and
issues of warrants and/or convertibles may occur with or without preferential
rights for shareholders of the Company and payment may be used for strategic
acquisitions, and may be made either in cash and/or by way of set-off or
contribution in kind or otherwise on specific terms. The number of shares
issued, or number of shares created in connection with exercise of warrants or
conversion of convertibles, shall not exceed 820,000.

For more information, please contact:

Michael Colérus, CFO
Tel: +46 70 341 34 72 E-mail: michael.colerus@scibase.com

SciBase Holding AB is required to disclose the information provided herein
pursuant to the Financial Instruments Trading Act. The information was submitted
for publication at 08:00 am on May 17, 2016.

About Skin Cancer

Skin cancer is one of the most common cancers in the world, accounting for
nearly half of all cancers. It has been estimated that nearly half of all
Americans who live to age 65 will develop skin cancer at least once. Malignant
melanoma is the most fatal form of skin cancer causing the majority (75%) of
deaths related to skin cancer. Worldwide, doctors diagnose about 230,000 new
cases of melanoma yearly.

About SciBase and Nevisense

SciBase AB is a Swedish medical technology company, headquartered in Stockholm
that has developed a unique point-of-care device for the accurate detection of
malignant melanoma. Its product, Nevisense, helps doctors to detect malignant
melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig
Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden.
Nevisense is based on substantial research and has achieved excellent results in
the largest clinical study ever conducted on the detection of malignant
melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and
is awaiting FDA clearance in the United States. Nevisense is based on a method
called Electrical Impedance Spectroscopy (EIS), which uses the varying
electrical properties of human tissue to categorize cellular structures and
thereby detect malignancies. SciBase is listed on Nasdaq First North (“SCIB”).
Avanza is the certified advisor. Further information is available on
www.scibase.com.